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p11, through unknown mechanisms, is required for
behavioral and cellular responses to selective sero-
tonin reuptake inhibitors (SSRIs). We show that
SMARCA3, a chromatin-remodeling factor, is a target
for the p11/annexin A2 heterotetrameric complex.
Determination of the crystal structure indicates that
SMARCA3 peptide binds to a hydrophobic pocket
in the heterotetramer. Formation of this complex
increases the DNA-binding affinity of SMARCA3
and its localization to the nuclear matrix fraction. In
the dentate gyrus, both p11 and SMARCA3 are highly
enriched in hilar mossy cells and basket cells. The
SSRI fluoxetine induces expression of p11 in both
cell types and increases the amount of the ternary
complex of p11/annexin A2/SMARCA3. SSRI-
induced neurogenesis and behavioral responses
are abolished by constitutive knockout ofSMARCA3.
Our studies indicate a central role for a chromatin-
remodeling factor in the SSRI/p11 signaling pathway
and suggest an approach to the development of
improved antidepressant therapies.
INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are currently the
most widely used class of antidepressants (Berton and Nestler,
2006). SSRI medications generally take several weeks to show
clinical efficacy, including mood elevation, despite their imme-
diate effect on serotonergic neurotransmission. This therapeutic
delay suggests the involvement of complicated downstream
mechanisms, including long-term changes in gene expression
and neuroplasticity. However, our knowledge of the molecular
mechanisms underlying the efficacy of long-term treatment
with SSRIs and of the pathophysiology of depression is still
rudimentary.p11 (S100A10) is a pivotal regulator of depression-like behav-
iors and a mediator of antidepressant responses (Svenningsson
et al., 2006). Despite the importance of p11 in the actions of
SSRIs, our knowledge about its underlying molecular mecha-
nisms is limited (Svenningsson et al., 2006). Annexin A2
(AnxA2) is a well-characterized binding partner for p11. AnxA2,
together with p11, plays a role in trafficking of membranous/
cytoplasmic proteins to plasma membrane or in providing
themwith firm anchorage at the plasmamembrane and the cyto-
skeletal structure (Rescher and Gerke, 2008). p11 and AnxA2
were also found to localize in the nucleus and interact with
nuclear proteins (Das et al., 2010; Liu and Vishwanatha, 2007),
although the precise roles of p11 and AnxA2 in the nucleus
have not been clearly defined. In this study, we have observed
that chronic treatment with an SSRI, fluoxetine (FLX), increases
the levels of the p11/AnxA2 complex. We have identified
SMARCA3, a chromatin-remodeling factor, as a downstream
target of the p11/AnxA2 complex. Our data indicate that the
p11/AnxA2/SMARCA3 pathway mediates both neurogenic and
behavioral responses to SSRIs.
RESULTS
Identification of SMARCA3 as a Specific Binding Partner
of p11/AnxA2 Complex
p11, together with AnxA2, forms a heterotetramer in cells.
However, it is not yet established that p11 exists in a protein
complex with AnxA2 in brain tissue. Here, we show that the
protein level of AnxA2 is drastically downregulated in the frontal
cortex and hippocampus of p11 knockout (KO) mice (Figure 1A),
despite unchanged levels of AnxA2 transcript (Figure 1B). In
contrast, the protein level of AnxA1, another annexin family
member, and of S100B, another S100 family member, was not
altered in the brain of p11 KO mice, indicating the specificity of
the physiological interaction between p11 and AnxA2 in the brain
(Figure 1A). We have also observed that p11 protein level in the
hippocampal lysates from AnxA2 KO mice is reduced (data not
shown). Given that components of a protein complex often stabi-
lize each other, the data strongly support the existence ofCell 152, 831–843, February 14, 2013 ª2013 Elsevier Inc. 831
Figure 1. p11/AnxA2 as an Antidepressant-
Regulated Protein Complex
(A) Brain lysates from frontal cortex and hippo-
campus of WT (+/+) and p11 KO (/) mice were
immunoblotted for p11, AnxA2, S100B, and
AnxA1.
(B) mRNA levels of p11 and AnxA2 in the
hippocampus were measured using qPCR in WT
(+/+) and p11 KO (/) mice. Data represent
mean ±SEM.
(C) Coimmunoprecipitation of p11 and AnxA2 from
lysates of N2a neuroblastoma cells and mouse
hippocampus using anti-p11 antibody. IP, immu-
noprecipitate.
(D) WT (+/+) or p11 KO (/) mice were adminis-
tered VEH or FLX for 2 weeks. Hippocampal
lysates were immunoblotted for p11, AnxA2, and
b-actin.
(E) Quantitation of the immunoblot shown in (D)
using infrared imaging system (Odyssey; LI-COR).
Data represent mean ±SEM. *p < 0.05 and **p <
0.01, t test. ns, nonsignificant; n.d., not detectable.a protein complex of p11 and AnxA2 in the brain. In addition, we
were able to coimmunoprecipitate AnxA2 with p11 from lysates
of the hippocampus as well as from lysates of N2a neuroblas-
toma cells (Figure 1C).
Previous studies showed that p11 was induced in the frontal
cortex (Svenningsson et al., 2006) and hippocampus (Warner-
Schmidt et al., 2010) by chronic administration of antidepres-
sants. In the present study, we observed concomitant upre-
gulation of p11 (170.4% ± 7.3% of p11(+/+)-vehicle (VEH) group;
p = 0.004) and of AnxA2 (167.1% ± 20.8%; p = 0.042) (Figures 1D
and 1E). This AnxA2 increase was not observed in p11 KO mice
(Figure 1E). Collectively, these results suggest that p11 and
AnxA2 exist as a protein complex, which can be induced by
antidepressant administration.
Next, we undertook a search for binding partners for p11/
AnxA2. To ensure the specificity of the interaction with the
p11/AnxA2 heterotetramer, we compared wild-type (WT) versus
C83S and C83Q mutants of p11, which prevent the interaction
between p11 and AnxA2 (Kube et al., 1992). C83S and C83Q
mutations in p11 significantly decreased the interaction with
AnxA2, without altering the interaction with endogenous p11 to
form a p11 dimer, suggesting that C83 mutations selectively
interfere with the heterotetramer formation, but not the homodi-
merization of p11 molecules (Figure S1A available online). After
transfection of p11 WT and C83 mutant plasmids into HEK293
cells, we isolated the protein complex of p11 using immunopre-
cipitation (Figure 2A). Four proteins with relative molecular mass
of 700, 260, 125, and 36 kDa were coprecipitated with WT p11
and were identified by mass spectrometry as AHNAK1 (AHNAK
nucleoprotein), SPT6 (suppressor of Ty 6 homolog S. cerevisiae),832 Cell 152, 831–843, February 14, 2013 ª2013 Elsevier Inc.SMARCA3 (SWI/SNF-related, matrix-
associated, actin-dependent regulator of
chromatin, subfamily A, member 3), and
AnxA2, respectively (Figure 2A). The iden-
tity of each protein was further confirmed
by immunoblotting with specific anti-bodies (Figure 2B). AHNAK1, SPT6, and SMARCA3 were copre-
cipitatedwithWT p11, and the interactionwas greatly reduced or
abolished by either C83S or C83Q mutation of p11, indicating
that the interaction likely needs AnxA2 binding to p11. AHNAK1
has been reported as a binding protein of p11/AnxA2 (Benaud
et al., 2004). We focused on SMARCA3 in the following studies
because of the potential physiological importance of this chro-
matin-remodeling factor. To evaluate the role of AnxA2 in the
intermolecular interaction, an in vitro pull-down assay using
GST-p11, AnxA2, and 35S-labeled SMARCA3 was used. The
SMARCA3 interaction was significantly increased by the addi-
tion of AnxA2 to the pull-down assay mixture (Figure S1B). The
interaction of SMARCA3 with p11/AnxA2 was further confirmed
by the inverse immunoprecipitation using anti-SMARCA3
antibodies (Figure 2C). Collectively, these results identified
SMARCA3 as a binding partner of p11/AnxA2.
SMARCA3 belongs to the family of SWI/SNF proteins that use
the energy of ATP hydrolysis to remodel chromatin in a variety of
nuclear processes, such as transcriptional regulation, and DNA
replication and repair (Debauve et al., 2008). SMARCA3 contains
multiple domain structures, including DNA-binding, helicase
ATP-binding, RING-type Zinc finger, and helicase C-terminal
domains (Figure 2D). We next performed in vitro pull-down assay
with a series of deletion constructs of SMARCA3 to determine
the binding region for p11/AnxA2 (Figures 2D, S1C, and S1D).
Although the serial deletion from the SMARCA3 C terminus
had no effect on the interaction with p11 (Figure S1C), the dele-
tion of the N terminus of SMARCA3 abolished the interaction
(Figure S1D), localizing a binding region close to the N terminus
of SMARCA3 (Figure 2D). Through sequence alignment between
Figure 2. Identification of the Binding
Proteins of p11/AnxA2 Complex
(A) Control vector (Vec.) and vectors containingWT
or interaction-defective mutants (C83S and C83Q)
of p11 were transfected into HEK293 cells. Pro-
teins that coprecipitated with WT are marked with
arrowheads (red). A nonspecific band is indicated
by a black arrowhead. The proteins were identified
by tandem mass spectrometry (black arrows).
(B) Immunoblots for AHNAK1, SPT6, SMARCA3,
AnxA2, and Flag-p11, as indicated.
(C) Coimmunoprecipitation of p11/AnxA2/
SMARCA3 complex from brain lysates by two
different anti-SMARCA3 antibodies.
(D) WT, deletion mutants, and a peptide were
tested for their interaction with p11/AnxA2.
(E) Putative p11-binding sequences of AHNAK1
(aa 5654–5671), AHNAK2 (aa 5382–5399), and
SMARCA3 (aa 26–42).
(F) Interaction of the AHNAK1 or SMARCA3
peptides with p11/AnxA2 was confirmed by the
pull-down assay of biotinylated peptides. Scram-
bled peptide was used as control.
See also Figure S1.AHNAK family proteins and the N terminus of SMARCA3, we
found a highly conserved putative binding motif, represented
byV-P-#-F-X-F (V, hydrophobic amino acid; P, proline; #, basic
amino acid; F, phenylalanine; X, any amino acid) (Figure 2E).
Next, we performed a peptide pull-down assay to validate p11/
AnxA2 binding to the putative binding motif. Indeed, the short
synthetic peptides from AHNAK1, AHNAK2, and SMARCA3
covering the putative motif were sufficient to bind to p11/
AnxA2 (Figure 2F; data not shown for AHNAK2 peptide).
Crystal Structure of p11/AnxA2 Bound to Its Ternary
Target, SMARCA3
To understand the molecular interaction of SMARCA3 and
AHNAK1 with p11/AnxA2 in detail, we conducted structural
studies of p11 and AnxA2 complexed with SMARCA3 or
AHNAK1 peptides. We have used a p11-AnxA2 fusion protein
(henceforth named p11-AnxA2 peptide cassette) in which
p11 (1-92) is connected to AnxA2 peptide with a nine aminoCell 152, 831–843,acid linker (QENLYFQGD) (Rezvanpour
et al., 2009) to generate complexes
with added SMARCA3 (P26-F39) and
AHNAK1 (G5654-F5668) peptides. Crys-
tals of the complexes with SMARCA3
peptide (Figure 3) and AHNAK1 peptide
(Figure S2) diffracted to 3.0 and 2.0 A˚
resolution, respectively. The structures
of the two complexes exhibited similar
recognition principles; although the pep-
tide sequences are different, the back-
bones of bound SMARCA3 and AHNAK1
peptides superimpose well with an rmsd
of 0.4 A˚. The higher-resolution structure
of the AHNAK1 peptide complex (FiguresS2A–S2F) proved useful in resolving ambiguities in the lower-
resolution structure of the SMARCA3 peptide complex (Figures
3A–3F).
We have solved the 3.0 A˚ crystal structure of the complex
between SMARCA3 (P26-F39) peptide and the p11-AnxA2
peptide cassette (Figures 3A and 3B; crystallization statistics in
Table S1). The fusion linker does not affect the binding between
p11 and AnxA2 peptide because we observe the same intermo-
lecular contacts in this complex as those reported previously
for nonlinked components (Re´ty et al., 1999). The p11-AnxA2
peptide cassette forms a symmetrical dimer, with individual
SMARCA3 peptides (electron density for bound peptide shown
in Figure 3C), binding eachmonomer in the dimer, while retaining
2-fold symmetry (Figures 3A and 3B). Complex formation
between SMARCA3 and p11-AnxA2 peptide cassette is medi-
ated by van derWaals contacts and hydrogen bond interactions,
whereby the SMARCA3 peptide interacts with elements of both
p11 and AnxA2 peptide (Figure 3D). Two highly conserved aminoFebruary 14, 2013 ª2013 Elsevier Inc. 833
Figure 3. Crystal Structure of SMARCA3Peptide Bound to p11-AnxA2PeptideCassette asBinary Complex and to p11 and Full-Length AnxA2
as Ternary Complex
(A) Ribbon view of crystal structure of p11-AnxA2 peptide cassette in complex with SMARCA3 peptide. p11 (blue and green) and AnxA2 peptide (salmon) are
shown in ribbon, with the bound SMARCA3 peptides (yellow) in stick representations.
(B) Space-filling (peptide) and electrostatic surface (p11-AnxA2 peptide cassette) view of the complex illustrating the positioning of the pair of SMARCA3peptides
within the binding groove of the dimeric complex.
(C) Omit 2FoFc electron densitymaps contoured at 1s level of bound SMARCA3 peptide in onemonomer of the complex. AnxA2 peptide (salmon) and p11 (blue)
are represented in ribbon views, SMARCA3 peptide (yellow) is represented in a stick view, and electron density contours are in green.
(D) Intermolecular contacts within one monomer of the complex between the SMARCA3 peptide (yellow) and p11 (blue)-AnxA2 peptide (salmon) cassette, with
hydrogen bonds depicted as red dashed lines.
(legend continued on next page)
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acids (Pro35 and Phe37) in the bound SMARCA3 peptide are
directed inward and anchored within a hydrophobic pocket
formed by residues from both p11 (Phe42, Ile55, Leu59, Leu75,
Leu79, and Ala82) and AnxA2 peptide (Leu8, Leu11, and
Leu13) in the complex (Figure 3E), with similar interactions
observed for Pro5664 and Phe5666 in the AHNAK1 complex
(Figure S2E). The complex is stabilized by additional intermolec-
ular hydrogen bonding interactions involving Phe33(SMARCA3)-
Asp60(p11) and Arg36/Glu38(SMARCA3)-Ser12/Glu14(AnxA2
peptide) pairs (Figure 3D), with similar intermolecular contacts
observed in the AHNAK1 complex (Figure S2D). In addition,
the two bound SMARCA3 peptides are aligned in a head-
to-head arrangement that is stabilized through intermolecular
hydrogen bond formation between their N-terminal residues
(Figure 3A). As expected, two point mutations (Pro35A and
Phe37Y) in the binding consensusmotif of SMARCA3 diminished
the interaction with p11/AnxA2 (Figure S3A). In addition, Leu13A
mutation of AnxA2 abolished the interaction with SMARCA3 with
no effect on p11 interaction, whereas Leu8A and Leu11A
mutation blunted the interaction to p11 as well as to SMARCA3
(Figure S3B), showing a unique role of the Leu13 residue in
creating a binding pocket for the ternary targets. These structural
and mutagenesis studies account for the molecular basis of the
preferential binding of SMARCA3 to p11/AnxA2.
We compared the structures of p11-AnxA2 peptide cassette in
the free (Protein Data Bank [PDB] ID code 1BT6) and SMARCA3
peptide-bound states following structural superimposition (Fig-
ure 3F). We observe that Asp60 in p11 is looped out from the
peptide-binding groove in the free state but flips inward by
4.8 A˚ on complex formation with the bound SMARCA3 peptide,
in the process forming additional intermolecular hydrogen bonds
(Figure 3D). In addition to this change, the Asp58-Asp64 loop
segment also undergoes a conformational change by shifting
toward and completes the peptide-binding groove on complex
formation (Figure 3F). A similar conformational transition is
observed on addition of AHNAK1 peptide to the p11-AnxA2
peptide cassette (Figure S2F). Indeed, the mutation on the p11
Asp60 residue abolished the interaction with SMARCA3 while
maintaining homodimerization of p11, as well as heterotetramer
formation with AnxA2, although the D60A mutant of p11 dis-
played a decrease in protein stability (Figure S3C). In our struc-
tures of complexes with bound SMARCA3 and AHNAK1 pep-
tides, the disulfide bridges observed for both p11 alone and
the p11-AnxA2 peptide cassette (Re´ty et al., 1999) are disrupted
due to the movement of the Asp58-Asp64 loop on complex
formation. As to the conformational change in AnxA2, we
observe an inward flip of Ser12 toward the peptide-binding site
by 4.6 A˚ for the SMARCA3-bound complex, thereby forming
intermolecular hydrogen bonds with bound peptide in the
complex (Figures 3D and 3F). In addition, due to this movement(E) Positioning of the conserved residues Pro35 and Phe37 of the bound SMARCA
(salmon) and p11 (blue).
(F) A view of the superimposed structures of the p11-AnxA2 peptide cassette in th
blue and AnxA2 peptide in salmon) states. Black arrows highlight the conformat
(G) Two views of 2.8 A˚ structure of SMARCA3 peptide (yellow) in stick represen
representation shown for two different angles.
See also Figures S2 and S3, and Tables S1 and S2.of Ser12, adjacent Leu13 in AnxA2 contributes to the closing of
an additional face of the hydrophobic pocket, thereby anchoring
the conserved residues Pro35 and Phe37 of bound SMARCA3
within the binding channel.
We have also successfully grown 2.8 A˚ crystals of SMARCA3
peptide bound to p11 and full-length AnxA2, with two views of
the structure of the ternary complex shown in Figure 3G (X-ray
statistics summarized in Table S2). Importantly, the crystal struc-
ture of p11/full-length AnxA2/SMARCA3 peptide illuminated the
three-dimensional organization of each component within the
ternary complex (Figure 3G). Full-length AnxA2 is composed of
an N-terminal p11-binding region and a C-terminal annexin
repeat region with opposing convex and concave sides (Gerke
et al., 2005). The convex side of AnxA2 faces the cellular
membrane to mediate PIP2 binding, and the concave side faces
away from the membrane. Although two N-terminal peptides of
AnxA2 contact the lateral/bottom side of the inverted p11 homo-
dimer, two N-terminal peptides of SMARCA3 are anchored on
the top position of the inverted p11 dimer while crossing each
other. On the other hand, C-terminal annexin repeat regions of
full-length AnxA2 are not involved in intermolecular recognition
in the ternary complex. Furthermore, the C-terminal ends of
the SMARCA3 peptides point downward, suggesting that the
rest of the C-terminal parts of SMARCA3 including DNA-binding,
ATP-dependent helicase, and Zinc finger domains are likely
positioned opposite to the convex side of the annexin repeat
region of AnxA2. This mode of ternary complex assembly may
leave C-terminal annexin repeat regions of AnxA2 free to execute
the binding to PIP2 and actin without steric hindrance. Taken
together, our structural data on the complex with full-length
AnxA2 implicate additional regulatory mechanisms through
extended molecular interactions via C-terminal annexin repeat
region.
Regulation of SMARCA3 Activity through Direct
Interaction with p11/AnxA2
SMARCA3was initially cloned as a regulatory factor that binds to
the target DNA motifs of several gene promoters and enhancers
and was shown to regulate the transcription of tissue-specific
target genes such as PAI-1, b-globin, and prolactin (Debauve
et al., 2008). It is noteworthy that the p11-binding region
(aa 34–39) of SMARCA3 is located adjacent to the DNA-binding
domain (aa 38–287) and seems to be partially overlapped. This
observation prompted us to examine whether p11/AnxA2 inter-
action may regulate the DNA-binding affinity of SMARCA3.
SMARCA3 was known to interact with the B box element in the
promoter of the PAI-1 gene (Ding et al., 1996). We carried out
an in vitro reconstitution assay using purified recombinant pro-
teins and the B box oligonucleotide immobilized on beads. The
oligonucleotide pull-down assay showed that SMARCA3 can3 peptide within a hydrophobic pocket formed by residues from AnxA2 peptide
e free (p11 in yellow and AnxA2 peptide in cyan) and SMARCA3-bound (p11 in
ional changes in p11 and AnxA2 peptide upon complex formation.
tation bound to full-length AnxA2 (salmon) and p11 (blue and green) in ribbon
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Figure 4. SMARCA3 Regulation by p11/
AnxA2 Complex
(A) The B box oligonucleotide was incubated with
the N-terminal domain of SMARCA3 (aa 1–350)
and p11 and/or AnxA2. Bound proteins were
immunoblotted.
(B) Quantitation of SMARCA3 bound to the B box
oligonucleotide.
(C) Whole cells (WC) and the nuclear matrix (NM)
were prepared from control (Control) or p11-
knockdown (KD) COS-7 cells and immunostained
with the indicated antibodies. Arrows indicate
knockdown cells, and open arrowheads show
nonknockdown cells. Scale bars, 20 mm.
(D) Whole-cell lysates and NM were prepared from
COS-7 cells transfected as indicated and im-
munoblotted for SMARCA3-V5 (a-V5), p11, AnxA2,
and Lamin-B (nuclear matrix marker).
(E) Transcriptional activity of SMARCA3 in N2a
cells after cotransfection of luciferase reporter
gene conjugated to PAI-1 promoter, together with
indicated plasmids. Immunoblots of cell lysates
and luciferase activity are shown.
(F) Transcriptional activity of SMARCA3 in Control
or p11-knockdown (KD) COS-7 cells transfected
with indicated SMARCA3 plasmids.
Mean ±SEM. *p < 0.05, **p < 0.01, and ***p < 0.001,
t test.form a quaternary complex together with p11/AnxA2 and the
B box oligonucleotide (Figure 4A). Furthermore, p11/AnxA2
interaction increases the DNA-binding affinity of SMARCA3 by
up to 2.5-fold, whereas the equivalent amount of AnxA2 alone
did not show any effect (Figure 4B).
The distinct subnuclear localizations of nuclear factors are
essential to conduct chromatin remodeling, transcription, repli-
cation, and mRNA processing (Zaidi et al., 2007). In fact, among
SWI/SNF family chromatin remodelers, the hBAF (Brg1-associ-
ated factors) complex is known to be targeted to the nuclear
matrix/chromatin through direct interaction with nuclear PIP2836 Cell 152, 831–843, February 14, 2013 ª2013 Elsevier Inc.and actin/actin-related protein (Rando
et al., 2002; Zhao et al., 1998). It is well
established that p11/AnxA2 binds to
PIP2 as well as actin (Rescher and Gerke,
2008). Thus, we examined the possibility
that p11/AnxA2 may regulate the subnu-
clear localization of SMARCA3. In the
whole-cell preparation, p11 is predomi-
nantly cytoplasmic, and a much less but
significant level of p11 is in the nucleus,
whereas SMARCA3 is mainly localized
inside the nucleus. Our unpublished stud-
ies with primary cultured neurons indicate
that p11, together with AnxA2, shuttles
between cytoplasm and nucleus (data
not shown). In the nuclear matrix, which
is prepared after cell permeabilization fol-
lowed by chromatin digestion, the pres-
ence and the colocalization of p11 and
SMARCA3 are evident (Figure 4C). Impor-tantly, the retention of SMARCA3 in the nuclear matrix is dramat-
ically reduced by the silencing of p11 expression with siRNA.
Consistent with that, biochemical fractionation of the nuclear
matrix revealed that WT SMARCA3 is in the nuclear matrix prep-
aration, whereas the P35A mutant, defective in p11/AnxA2 inter-
action, is not (Figure 4D), confirming the importance of the p11/
AnxA2 complex in the subnuclear localization of SMARCA3.
Taken together, p11/AnxA2 not only increases the DNA-
binding affinity of SMARCA3 but also anchors SMARCA3 to
the nuclear matrix presumably via the interaction of AnxA2 with
actin and PIP2.
Figure 5. SSRI Regulates p11 Expression in
Mossy Cells and Basket Cells in the Dentate
Gyrus
(A) Cell types expressing [p11]-EGFP in the dentate
gyrus. CRT (hilar mossy cells [MC]), parvalbumin
(PV, subpopulation of basket cells [BC(PV+)]),
calbindin (CBD, mature granule cells [GC]) neuro-
peptide Y (NPY, hilar interneurons perforant path
[HIPP]), glial fibrillary acidic protein (GFAP, astro-
cytes), and nestin (neural stem cells [SC]) were
used to identify cell types. Solid arrowheads indi-
cate representative doubly labeled cells. Open
arrowheads show cells labeled only with markers.
Scale bars, 20 mm.
(B) Distinct laminar projections of mossy cells
and parvalbumin-positive basket cells in the den-
tate gyrus. GCL, granule cell layer; OML, outer
molecular layer. Scale bar, 100 mm.
(C–E) Induction of [p11]-EGFP in dentate gyrus by
chronic SSRI. The dentate gyrus slices were
costained with anti-EGFP antibody (C and D) and
either anti-CRT (C) or anti-PV (D) antibodies. Scale
bars, 100 mm. EGFP intensity was quantitated in
the indicated subregions (E). Values were nor-
malized to fluorescence intensity in OML. Data
represent mean ±SEM (n = 5–6 mice per group).
*p < 0.05 and **p < 0.01, t test. Rel. Fluorescence,
relative fluorescence.
See also Figure S4.To assess the functional consequence of p11-AnxA2 interac-
tion in the transcriptional activity of SMARCA3, we utilized a
PAI-1 promoter-driven luciferase reporter assay. First, we exam-
ined the effect of overexpression of the p11/AnxA2 complex in
N2a cells, which express low endogenous levels of p11 and
AnxA2. Cotransfection of SMARCA3 with p11 and AnxA2 poten-
tiated luciferase activity (Figure 4E). In addition, we examined the
effect of p11 gene silencing in COS-7 cells, which express rela-
tively higher endogenous levels of p11 and AnxA2. The silencing
of the p11 gene leads to the downregulation of SMARCA3-
mediated luciferase activity (Figure 4F). In the same experimental
set, we also compared WT SMARCA3 with its mutants (P35A,
F37Y) defective in the interaction with the p11/AnxA2 complex.
As expected, SMARCA3-mediated luciferase activity was abol-
ished in the two mutants (Figure 4F). Collectively, these results
suggest that p11/AnxA2 regulates transcriptional activity of
SMARCA3 by controlling the DNA-binding affinity of SMARCA3,
as well as its localization.
Regulation of the p11/AnxA2/SMARCA3 Complex in
Hilar Mossy Cells and Basket Cells in the Dentate Gyrus
p11 mediates the actions of antidepressants (Svenningsson
et al., 2006). Chronic antidepressant administration increased
the level of p11 in the hippocampus (Figures 1D and 1E). Antide-
pressant actions including neurogenesis require several weeksCell 152, 831–843,to show therapeutic effects. SMARCA3-
mediated regulation of transcription may
be associated with the therapeutic delay.
Our previous study showed that p11 is
expressed in GABAergic basket cells inthe dentate gyrus and might play a critical role in antidepres-
sant-induced hippocampal neurogenesis (Egeland et al., 2010).
We thus examined the neuronal types expressing p11 and
SMARCA3 in the dentate gyrus.
We took advantage of BAC (bacterial artificial chromosome)
transgenic mice (Heintz, 2001), in which the expression of
EGFP reporter is driven by p11 promoter activity ([p11]-EGFP).
The excellence of immunostaining analysis using anti-EGFP anti-
body enabled us to visualize the entire neuronal processes of
the neurons expressing p11. Because EGFP-positive neurons
in the BAC-[p11]-EGFPmice are doubly positive for the immuno-
staining of endogenous p11, EGFP-positive neurons represent
p11-expressing neurons (Figure S4A). p11-expressing cells as-
sessed with [p11]-EGFP signal localize in the hilus region of
the dentate gyrus (Figure 5A). To identify neuronal types for the
p11-expressing neurons, hippocampal sections from BAC-
[p11]-EGFP transgenic mice were doubly stained with EGFP
and neuronal-type markers. Notably, [p11]-EGFP reporter signal
was found to be enriched both in calretinin (CRT)-positive mossy
cells and in PV-positive basket cells, whereas the signal was
negligible in granule cells and is rarely (<5%) observed in HIPP
cells (Figure 5A). Furthermore, p11 expression is not observed
in astrocytes or neural stem cells (Figure 5A).
We next examined whether p11 expression in hippocampal
neuronal subpopulations is altered in response to antidepressantFebruary 14, 2013 ª2013 Elsevier Inc. 837
Figure 6. SMARCA3 Expression in Mossy
Cells and Basket Cells in the Dentate Gyrus
(A) Dentate gyrus slices from WT (top) or
SMARCA3 KO mice (bottom) stained with anti-
SMARCA3 antibody (red) and nuclear dye DraQ5
(blue). Scale bars, 100 mm.
(B) Neuronal cell types expressing SMARCA3
in the dentate gyrus. Scale bars, 20 mm. Repre-
sentative cells doubly labeled are indicated by
arrowheads.
(C) Coexpression of [p11]-EGFP and SMARCA3.
BAC-[p11]-EGFP mice were stained with anti-
EGFP and anti-SMARCA3 antibodies. Represen-
tative cells doubly labeled are indicated by
arrowheads. Scale bar, 20 mm.
(D and E) Level of SMARCA3 is not altered by FLX
administration for 2 weeks. Hippocampal lysates
were immunoblotted for SMARCA3 and b-actin
(D). mRNA level of SMARCA3 in the hippocampus
was measured using qPCR (E). Data repre-
sent mean ±SEM (n = 6–7 mice per group). ns,
nonsignificant.
(F) Formation of p11/AnxA2/SMARCA3 complex is
increased after treatment with FLX for 2 weeks.
SMARCA3 was immunoprecipitated from hippo-
campal lysates. Total lysates and immunoprecip-
itates (IPs) were immunoblotted for SMARCA3,
p11, and AnxA2.
See also Figure S5.administration. We took advantage of the distinct laminar
segregation of the two types of p11-expressing neurons. The
mossy cells assessed by CRT expression locate their soma
and dendrites within the deep hilus and project their axonal
arbor to the inner molecular layer (IML), whereas a subpopula-
tion of basket cells visualized by PV staining locates its somas
in the hilar border and projects its axons to the granule cells
within the granular cell layer (GCL) (Figure 5B). Because p11
is mainly enriched in mossy cells and basket cells, the [p11]-
EGFP signal in the hilus and IML represents p11 promoter
activity in mossy cells, and the signal of EGFP in GCL does
for basket cell activity. BAC-[p11]-EGFP mice were treated
with FLX for 2 weeks, and [p11]-EGFP signal was examined
in the areas of hilus, IML, and GCL (Figures 5C–5E). Because
a high density of serotonergic innervation prevails in the caudal
part of the hippocampal formation, whereas the rostral part
receives only a moderate-to-weak serotonergic innervation
(Bjarkam et al., 2003; Gage and Thompson, 1980), the caudal
part (bregma 2.5 to 4.0) of the dentate gyrus was used for
the analysis. FLX treatment increased [p11]-EGFP in the den-
tate gyrus (Figures 5C and 5D). Quantitative analysis revealed
that FLX increased [p11]-EGFP intensity in hilus and IML as
well as in GCL, suggesting p11 induction in mossy cells and
basket cells (Figure 5E). p11 is also induced in the rostral part
of the hippocampus but with less potency (Figure S4B).
AnxA2, together with p11, is induced by FLX and requires
p11 for its protein stability (Figures 1D and 1E). Conversely,
p11 protein requires AnxA2 for its protein stability (data not838 Cell 152, 831–843, February 14, 2013 ª2013 Elsevier Inc.shown). Thus, AnxA2 is also likely to be induced in the same
neurons.
We examined the expression of SMARCA3 in the dentate
gyrus by immunohistochemistry. The specificity of the immuno-
staining was tested using SMARCA3 KO mice. SMARCA3 KO
mice were generated by targeting exons 11–13 of the SMARCA3
gene (Figure S5A). Immunoblotting (Figures S5B and S5C) and
immunohistochemistry (Figure 6A) confirmed the absence of
SMARCA3. SMARCA3 is expressed primarily in the hilar area
of the dentate gyrus (Figure 6A), where it is enriched in mossy
cells and parvalbumin-positive basket cells (Figure 6B), and is
expressed in [p11]-EGFP-positive cells (Figure 6C).
In contrast to p11 and AnxA2 (Figures 1D and 1E), the levels of
SMARCA3 protein (Figure 6D) and mRNA (Figure 6E) were not
altered after treatment with FLX. Analysis of hippocampal
lysates, following immunoprecipitation of SMARCA3, revealed
that chronic FLX administration increased the ternary complex
of p11/AnxA2/SMARCA3 by about 2.3-fold (Figure 6F). Thus,
p11 and AnxA2 induction facilitates the assembly of the p11/
AnxA2/SMARCA3 complex. Taken together, these results iden-
tify the mossy cells and the basket cells in the dentate gyrus as
primary neuronal types for SSRI/p11/SMARCA3 signaling.
SMARCA3 Is Required for Neurogenic and Behavioral
Response to Chronic SSRI Administration
p11 KO results in the loss of enhanced hippocampal neurogen-
esis and behavioral change in response to chronic antidepres-
sant treatment (Egeland et al., 2010), suggesting a crucial role
Figure 7. SMARCA3 Is Required for SSRI-
Induced Neurogenesis and Behavioral
Changes
(A and B) FLX-induced cell proliferation in WT and
SMARCA3 KO mice. WT (+/+) and SMARCA3 KO
(/) mice were administered VEH or FLX for
14 days and labeledwith BrdU for the last 2 hr prior
to perfusion. (A) Immunostaining with anti-BrdU.
Scale bars, 100 mm. (B) Quantitation of BrdU-
positive cells in the subgranular zone (n = 6–8 mice
per group).
(C and D) FLX-induced increase of DCX-positive
cells in WT and SMARCA3 KO mice. (C) Immu-
nostaining with anti-DCX. Scale bars, 20 mm. (D)
Quantitation of DCX-positive cells in the sub-
granular and granular zone (n = 6–8 per group).
(E and F) Survival of newborn cells in WT and
SMARCA3KOmice treatedwith VEH or FLX. BrdU
was injected for three consecutive days prior to
FLX administration for 28 days. (E) Immunostaining
with anti-BrdU and anti-NeuN. Scale bars, 100 mm.
(F) Quantitation of BrdU-positive cells.
(G and H) Behavior was assayed using (G) the NSF
paradigm after chronic administration of VEH or
FLX (4 weeks, n = 14–16 per group), or (H) the SPT
in NS or RS mice after chronic administration of
VEH or eCIT (4 weeks, n = 8–11 per group).
All data represent mean ±SEM. *p < 0.05, **p <
0.01, and ***p < 0.001, two-way ANOVA followed
by the post hoc Bonferroni test. ns, nonsignificant.
See also Figure S6 and Table S3.for p11 and its downstream signaling pathways in those
antidepressant actions. We examined here whether SMARCA3,
as a downstream signaling molecule of p11, might mediate
chronic antidepressant-induced hippocampal neurogenesis
and behaviors.
Adult neurogenesis is controlled by multistep processes
including the proliferation of neural progenitors, differentiation,
and maturation into functional granule neurons (Ming and
Song, 2011). We examined proliferation using in vivo BrdU
labeling of the neural progenitors in the S phase in WT and
SMARCA3 KO mice. A significant increase was observed in
the number of BrdU-labeled neural progenitors in WT miceCell 152, 831–843,treated with FLX (160.6% ± 13.7% of
VEH group; p < 0.01), but not in
SMARCA3 KO mice (Figures 7A and
7B). We also carried out an alternative
assay measuring an endogenous mitotic
marker Ki-67. Ki-67-positive cells were
significantly increased in response to
FLX in WT mice (143.8% ± 8.6%; p <
0.01), but not in SMARCA3 KO mice
(Figures S6A and S6B), confirming the
results of the BrdU assay.
We next analyzed the expression level
of doublecortin (DCX), a marker for
immature neurons, which represents a
snapshot of newborn cells undergoing
neuronal maturation and differentiation(Couillard-Despres et al., 2005). DCX immunofluorescence
signal was increased by chronic FLX administration in WT mice
(218.4% ± 18.0%; p < 0.001), but not in SMARCA3 KO mice
(Figures 7C and 7D). Chronic FLX administration promotes the
newborn cells to survive at postmitotic stages and also to
becomemature neurons (Wang et al., 2008). Chronic FLX admin-
istration greatly increased the survival of the BrdU-labeled
newborn cells in WT mice (288.2% ± 21.1%; p < 0.01), but the
effect of FLX was attenuated in SMARCA3 KO mice (196.0% ±
20.3%; p < 0.05) (Figures 7E and 7F). Taken together, these
results indicate that SMARCA3 contributes to multiple stages
of antidepressant-stimulated neurogenesis, and this phenotypeFebruary 14, 2013 ª2013 Elsevier Inc. 839
of SMARCA3 KOmice is reminiscent of that observed in p11 KO
mice (Egeland et al., 2010).
Next, we investigated the functional significance of the p11/
AnxA2/SMARCA3 complex for SSRI-induced behavioral
changes. WT and SMARCA3 KOmice did not display a baseline
difference in locomotor activity (open field test, Figure S6C),
depressive behaviors (tail suspension test [TST] and sucrose
preference test [SPT], Figures S6D and S6E), or anxiety behav-
iors (light/dark and elevated plus maze tests, Figures S6F and
S6G). Novelty-suppressed feeding (NSF) is believed to represent
depression-like and anxiety behavior, and this test is commonly
used to measure the chronic effect of antidepressants (David
et al., 2009; Surget et al., 2011). p11 KO mice are refractory to
behavioral change in response to chronic FLX administration in
the NSF test (Egeland et al., 2010; Schmidt et al., 2012). In the
same model, we analyzed the behavior of SMARCA3 KO mice.
Chronic treatment with FLX shortened latency to feed compared
to VEH treatment in WT mice (VEH versus FLX, 279 ± 13 versus
187 ± 20; p < 0.01), but not in SMARCA3 KO mice (Figure 7G),
as with p11 KO mice (Egeland et al., 2010). Neither FLX nor
SMARCA3 KO caused any significant effect on home cage
feeding (Figure S6H) or body weight (data not shown).
Anhedonia is a core symptom of human depression (Berton
and Nestler, 2006), and a chronic stress-induced decrease in
sucrose preference in rodents is regarded as a sign of a hedonic
deficit (Katz, 1982), which can be treated with chronic SSRI. We
examined the effect of chronic administration of escitalopram
(eCIT, another SSRI) on the behaviors of nonstressed (NS)
or restraint-stressed (RS) mice in the SPT. Daily restraint for
14 days induced a reduction of sucrose consumption in both
WT (NS plus VEH versus RS plus VEH, 100% ± 12% versus
68% ± 8%, respectively) and SMARCA3 KO mice (NS plus
VEH versus RS plus VEH, 97% ± 6% versus 61% ± 8%, respec-
tively). Poststress treatment with eCIT recovered sucrose
consumption to the normal level in WTmice (RS plus VEH versus
RS plus eCIT, 68% ± 8% versus 99% ± 13%, respectively), but
not in SMARCA3 KO mice (Figure 7H). No differences were
observed between WT and SMARCA3 KO mice as well as
among the experimental groups used for the SPT with regard
to their locomotor activities (Figure S6I). Notably, the behavioral
despair in the TST is known to be treated by acute SSRI, whereas
the therapeutic effect of SSRI in the NSF and SPT requires
chronic treatment. SMARCA3 KO did not alter the effect of acute
administration of eCIT in the TST (Figure S6J). Taken together,
our results suggest a crucial role for SMARCA3 in p11-depen-
dent neurogenic and behavioral response to chronic antidepres-
sant administration.
DISCUSSION
Molecular Interaction of p11/AnxA2 with SMARCA3
p11 and AnxA2 cooperate to create a unique binding pocket, but
the optimal binding condition is not achieved without conforma-
tional changes associated with target binding. Upon interaction
with the SMARCA3 peptide, both Asp60 in p11 and Ser12
in AnxA2 flip inward toward the peptide-binding groove,
forming additional intermolecular hydrogen bonds (Figures
3D–3F). Similar intermolecular contacts were also observed in840 Cell 152, 831–843, February 14, 2013 ª2013 Elsevier Inc.the AHNAK1 complex (Figures S2D–S2F). These findings
support an induced-fit model for the assembly of the p11/
AnxA2/SMARCA3 complex. Among the key residues found in
the binding pocket, the role of Ser12 (AnxA2) is of particular
interest because this residue is regulated by phosphorylation
(Jost and Gerke, 1996), which may interfere with high-affinity
binding of ternary targets.
The current study identifies a binding motif, which is repre-
sented as f-P-#-F-X-F, and can be used for in silico analysis
to identify binding targets of p11/AnxA2. Our binding motif is
different from the p11-binding sequences previously reported
for TRPV5/6 (VATTV) (van de Graaf et al., 2003) and TASK1
(RRSSV) (Girard et al., 2002). It is possible that the p11/AnxA2
heterotetramer has additional binding pocket(s) on the surface.
Regulation of SMARCA3 Function by Interaction with
the p11/AnxA2 Complex
Most chromatin remodelers, including four well-characterized
subfamily members (SWI/SNF, INO80/SWR1, ISWI, and CHD),
form a large multisubunit complex with a core ATPase motor
subunit and unique accessory/regulatory subunits (Hargreaves
and Crabtree, 2011). The core subunit displays DNA- and nucle-
osome-dependent ATPase activity, and the accessory/regula-
tory subunits are essential for the function of the core ATPase
subunit, by facilitating the interaction with the transcriptional
regulatory factors, mediating the indirect binding to DNA and/
or modified histones, and targeting the complex to subnuclear
locations (Mohrmann andVerrijzer, 2005). SMARCA3, a relatively
uncharacterized member of the SWI/SNF protein family, is
composed of multiple functional domains, including a DNA-
binding domain, a SWI2/SNF2 ATPase domain, a RING-type
zinc finger domain for the binding to RFBP, a Type IV P-type
ATPase, and a C-terminal domain for the binding of transcription
factors such as Sp1, Sp3, Egr1, and cRel (Debauve et al., 2008)
(Figure 2D). Although p11 and AnxA2 stabilize each other as
structural components of a protein complex (Figure 1), the levels
of p11 and AnxA2 are not altered in SMARCA3 KOmice (Figures
S5B and S5C), and the level of SMARCA3 is not altered in p11
KO mice (data not shown). Thus, p11 and AnxA2 act as regula-
tory proteins but are not likely structural core components of
SMARCA3. Notably, the DNA-binding domain at the N-terminal
side of the ATPase domain mediates the sequence-dependent
binding of SMARCA3 to the target DNA (Debauve et al., 2008).
p11/AnxA2 facilitates the DNA-binding affinity of SMARCA3
(Figures 4A and 4B). Most chromatin-remodeling complexes,
including SMARCA3, display DNA- and/or nucleosome-depen-
dent ATPase activity (Hargreaves and Crabtree, 2011). There-
fore, it is conceivable that the enhanced DNA binding of
SMARCA3, upon the interaction with p11/AnxA2, may lead to
the activation of SMARCA3 to initiate ATP-dependent chromatin
remodeling of the target genes. Thus, p11/AnxA2 binding to
SMARCA3 would open the chromatin structure and recruit
specific transcription factors bound to the C-terminal domain
of SMARCA3 to the specific locus of the genomic DNA.
Critical nuclear events such as gene expression, replica-
tion, and repair processing occur at a distinct subnuclear
region, the nuclear matrix, which is composed of nuclear
lamins, nuclear actin/actin-related proteins, and phospholipids
(Barlow et al., 2010; Zaidi et al., 2007). Indeed, key gene regula-
tory machineries such as transcription factors, chromatin-
remodeling complexes, RNA polymerase II, and processing
factor SC35 are associated with nuclear matrix structures (Zaidi
et al., 2007). p11/AnxA2 mediates the subnuclear targeting of
SMARCA3 (Figures 4C and 4D). The subnuclear targeting of
SMARCA3 is likely controlled by intrinsic phospholipid- and
actin-binding properties of AnxA2 (Gerke et al., 2005). Our
crystal structure of p11/full-length AnxA2/SMARCA3 peptide
visualized the spatial organization of each component in the
ternary complex, in which the p11 dimer is ideally positioned in
the core of the complex to link SMARCA3 to AnxA2 (Figure 3G).
Thus, our current model is reminiscent of the role of p11/AnxA2
in mediating the membrane translocation of AHNAK1 (Benaud
et al., 2004). Both SMARCA3 and AHNAK1 use the interaction
with p11/AnxA2 to localize properly to the distinct subcellular
sites where they become functionally active.
p11/AnxA2/SMARCA3 Complex in Antidepressant
Action
p11/AnxA2/SMARCA3 complex-mediated hippocampal neuro-
genesis may contribute to the behavioral response to SSRIs.
However, the involvement of hippocampal neurogenesis in
depression andantidepressant-inducedbehavioral change is still
controversial (Hanson et al., 2011). Such neurogenesis has been
associated with mood, stress responses, and antidepressant
effects in some studies (Santarelli et al., 2003; Snyder et al.,
2011; Surget et al., 2011), but not in others (Bessa et al., 2009).
p11 and SMARCA3 are enriched in mossy cells and basket
cells but not detectable in neural progenitor cells. Thus, the
regulation of SSRI-induced neurogenesis by the p11/AnxA2/
SMARCA3 signaling pathway is non-cell autonomous. In fact,
GABAergic interneurons play an important role in the differentia-
tion, development, and integration of newborn neurons (Ge et al.,
2006; Tozuka et al., 2005). Specifically, interneuronal GABA
release is thought to act directly on neural progenitor cells and,
due to an age-specific increase in intracellular chloride levels in
these young cells, causes an atypical depolarization that subse-
quently affects neurogenic processes (Tozuka et al., 2005). The
synaptic regulation of granule cells by basket and mossy cells
may contribute to the neurogenic and behavioral responses to
SSRIs. It has been suggested that, upon activation by local
inputs from the granule cells in the dentate gyrus, glutamatergic
mossy cells primarily provide excitatory feedback to the granule
cells through their axonal projections to the IML and also provide
excitatory drive to local GABAergic HIPPs in the hilus (Henze and
Buzsa´ki, 2007; Scharfman, 1995). The basket cells primarily
provide feedforward inhibition to the granule cells in response
to excitatory inputs from the entorhinal cortex and feedback inhi-
bition to the granule cells in response to excitatory inputs from
the granule cells (Houser, 2007). Thus, despite their relatively
low abundance (33 104mossy cells and 0.53 104 basket cells
versus 1 3 106 granule cells in rat), the mossy cells and basket
cells regulate the flow of extrinsic input to the dentate gyrus
through modulation of the activity of the granule cells and/or
the HIPPs, and such regulation is important to generate the
distinct oscillation patterns of neuronal excitation in the dentate
gyrus (Amaral et al., 2007; Henze and Buzsa´ki, 2007).In this study, we have identified and characterized a nuclear
protein complex mediating chronic actions of SSRIs. Many inter-
esting questions have been raised as a result of this study: What
are the roles of p11 and SMARCA3 in the excitability and
synaptic transmission of basket cells and mossy cells? Which
genes are regulated by the p11/AnxA2/SMARCA3 complex in
basket cells and mossy cells? Which of these genes contribute
to the neurogenic and behavioral responses to antidepressants?
Current and future studies of the p11/AnxA2/SMARCA3
pathway should contribute not only to our understanding of
SSRI actions but also provide molecular and cellular targets for
the development of advanced therapeutics for mood and anxiety
disorders.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice
All procedures involving animals were approved by the Rockefeller University
Institutional Animal Care and Use Committee and were in accordance with the
National Institutes of Health guidelines. The constitutive SMARCA3 KO mice
were generated in Taconic-Artemis (Germany) and maintained at The Rock-
efeller University. The BAC-[p11]-EGFP transgenic line (GENSAT; Clone No.
HC85) was provided by GENSAT (Gong et al., 2002). The mouse breeding
and drug treatment methods are in the Extended Experimental Procedures.
Crystallization and Structure Determination of p11/AnxA2/
SMARCA3 and p11/AnxA2/AHNAK1 Complexes
Details of protein preparations, protein expression, purification, crystallization
conditions, data collection, and refinement are included in Extended Experi-
mental Procedures.
Preparation of Nuclear Matrix Fraction
Cells were incubated with cell-permeable crosslinker, DSP (1 mM), and
extracted with CSK buffer containing 0.5% NP40. After chromatin digestion
with DNase I and then elution with 0.25 M (NH4)2SO4, the nuclear matrix
fraction was scraped for the biochemical assay or fixed with 2% parafor-
maldehyde for immunocytochemistry (detailed description is in Extended
Experimental Procedures).
Histological Methods
Immunostaining was carried out using the standard free-floating method.
Detailed description of antibody preparation, antigen retrieval, image acquisi-
tion, and quantification is in Extended Experimental Procedures.
Behavioral Analysis
Mood and anxiety-related behaviors (NSF, SPT, TST, light-dark box test, and
elevated plus maze) and locomotor activity (open field test) were tested as
described in Extended Experimental Procedures.
Data Analysis and Statistics
All data are presented as mean ±SEM. Two group comparisons were done by
two-tailed, unpaired Student’s t test. Multiple group comparisons were as-
sessed using a one-way or two-way ANOVA, followed by the post hoc
Newman-Keuls test or Bonferroni test, respectively, when significant main
effects or interactions were detected. Statistical significance was set at p <
0.05 level. Summary of statistical analysis for animal experiments is included
as Table S3.
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Coordinates and structure factors for p11-AnxA2 peptide cassette in complex
with AHNAK1 peptide (PDB 4HRG) and SMARCA3 peptide (PDB 4HRH) and
full-length p11/AnxA2 heterotetramer in complex with SMARCA3 peptide
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